Vertex has a busy catalyst calendar in 2H24 which include next-gen CF approval, acute pain approval for their first-in-class pain drug, and additional data sets in chronic pain." A pharmacist ...

Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price ...

BOSTON, October 25, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous ...

Jupiter Endovascular, Inc. announced that the first patient has been treated in the SPIRARE II United States pivotal study of ...

Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts ...

Making a noteworthy insider sell on October 9, ITEM SECOND IRR TRUST FBO JACOB J WESTPHAL ua of JEFFREY R WESTPHAL dated October , 10% Owner at Vertex VERX, is reported in the latest SEC filing.

More than three-quarters (77%) of health care providers surveyed stated that treating moderate-to-severe acute pain with ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.39% higher to $455.31 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX ...